IBTA vs DSGX vs CDLX

For growth investors, The Descartes Systems Group Inc.

(DSGX) is the stronger pick with 14. 4% revenue growth year-over-year, versus -16. 2% for Cardlytics, Inc. (CDLX). The Descartes Systems Group Inc. (DSGX) offers the better valuation at 38. 4x trailing P/E (39. 3x forward), making it the more compelling value choice. Analysts rate Ibotta, Inc. (IBTA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Descartes Systems Group Inc.

(DSGX) is the cheapest at 38. 4x versus Ibotta, Inc. at 305. 9x.

Over the past 5 years, The Descartes Systems Group Inc.

(DSGX) delivered a total return of +19. 7%, compared to -99. 2% for Cardlytics, Inc. (CDLX). Over 10 years, the gap is even starker: DSGX returned +295. 4% versus CDLX's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Descartes Systems Group Inc.

(DSGX) is the lower-risk stock at 0. 71β versus Cardlytics, Inc. 's 3. 18β — meaning CDLX is approximately 349% more volatile than DSGX relative to the S&P 500. On balance sheet safety, The Descartes Systems Group Inc. (DSGX) carries a lower debt/equity ratio of 1% versus 9% for Ibotta, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Descartes Systems Group Inc.

(DSGX) is pulling ahead at 14. 4% versus -16. 2% for Cardlytics, Inc. (CDLX). On earnings-per-share growth, the picture is similar: Cardlytics, Inc. grew EPS 50. 1% year-over-year, compared to -95. 3% for Ibotta, Inc.. Over a 3-year CAGR, IBTA leads at 17. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Descartes Systems Group Inc.

(DSGX) is the more profitable company, earning 22. 5% net margin versus -44. 4% for Cardlytics, Inc. — meaning it keeps 22. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DSGX leads at 32. 3% versus -20. 2% for CDLX. At the gross margin level — before operating expenses — IBTA leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IBTA: 121.

7% to $81. 38.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, The Descartes Systems Group Inc.

(DSGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +295. 4% 10Y return). Cardlytics, Inc. (CDLX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DSGX: +295. 4%, CDLX: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IBTA (Technology) and DSGX (Technology) and CDLX (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.